Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
64%(7 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_4
1
8%
Ph phase_3
8
67%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
8(66.7%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Other(1)

Detailed Status

Completed11
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 21 (8.3%)
Phase 38 (66.7%)
Phase 41 (8.3%)

Trials by Status

unknown18%
completed1192%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants

NCT00213265
completedphase_3

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

NCT02736240
completedphase_3

A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China

NCT01692886
completedphase_3

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

NCT00474539
completedphase_3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

NCT00368966
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00213265Phase 3

Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants

Completed
NCT02736240Phase 3

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Completed
NCT01692886Phase 3

A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China

Completed
NCT00474539Phase 3

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Completed
NCT00368966Phase 3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Completed
NCT00366678Phase 3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Completed
NCT00366340Phase 3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Completed
NCT00164411Phase 1

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine

Completed
NCT00689351Phase 2

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea

Completed
NCT01346007Phase 4

Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome

Unknown
NCT00475033Phase 3

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Completed
NCT00488826Phase 1

Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12